Assessment of Anti-RANKL Antibody in Post-menopausal Women
Phase I Trial of Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Fully Human Monoclonal Antibody to RANKL (TK006) in Post-menopausal Women.
Sponsor: Jiangsu T-Mab Biopharma Co.,Ltd
A PHASE1 clinical study on Osteoporosis, this trial is ongoing. The trial is conducted by Jiangsu T-Mab Biopharma Co.,Ltd and has accumulated 7 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE1
-
Apr 2020 — Jan 2021 [monthly]
Unknown Status PHASE1
Status: Enrolling By Invitation → Unknown Status
-
Jun 2018 — Apr 2020 [monthly]
Enrolling By Invitation PHASE1
▶ Show 2 earlier versions
-
Mar 2018 — Jun 2018 [monthly]
Enrolling By Invitation PHASE1
Status: Not Yet Recruiting → Enrolling By Invitation
-
Sep 2017 — Mar 2018 [monthly]
Not Yet Recruiting PHASE1
First recorded
Aug 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Jiangsu T-Mab Biopharma Co.,Ltd
For direct contact, visit the study record on ClinicalTrials.gov .